The Hemorrhagic Cystitis (Haemorrhagic Cystitis) drugs in development market research report provides comprehensive information on the therapeutics under development for Hemorrhagic Cystitis (Haemorrhagic Cystitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemorrhagic Cystitis (Haemorrhagic Cystitis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemorrhagic Cystitis (Haemorrhagic Cystitis) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Hemorrhagic Cystitis (Haemorrhagic Cystitis) by five companies/universities/institutes. The top development phase for Hemorrhagic Cystitis (Haemorrhagic Cystitis) is preclinical with three drugs in that stage. The Hemorrhagic Cystitis (Haemorrhagic Cystitis) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hemorrhagic Cystitis (Haemorrhagic Cystitis) pipeline products market are: Urigen Pharmaceuticals, Lipella Pharmaceuticals and AlloVir.
The key targets in the Hemorrhagic Cystitis (Haemorrhagic Cystitis) pipeline products market include Sirtuin (SIRT or EC 2.3.1.), and Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16).
The key mechanisms of action in the Hemorrhagic Cystitis (Haemorrhagic Cystitis) pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with one drug in Phase II. The Hemorrhagic Cystitis (Haemorrhagic Cystitis) pipeline products include two routes of administration with the top ROA being Intravenous and two key molecule types in the Hemorrhagic Cystitis (Haemorrhagic Cystitis) pipeline products market including Small Molecule, and Cell Therapy.
Hemorrhagic Cystitis (Haemorrhagic Cystitis) overview
Hemorrhagic cystitis is a bladder inflammation that causes the lining of the bladder to bleed. It is caused by toxins, pathogens, radiation, drugs, and certain medical conditions. It can also be a complication of cyclophosphamide, ifosfamide, and radiation therapy. Symptoms include hematuria, blood clots in urine, dysuria, fever, inability to urinate, and loss of bladder control. Diagnosis can be done through clinical presentation and urinalysis. IV fluids, embolization, hyperbaric oxygen therapy, and intravesical therapy are the treatment options.
For a complete picture of Hemorrhagic Cystitis (Haemorrhagic Cystitis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
